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1 These authors contributed equally to this work.We investigated the effect of a periodontal pathogen, Porphyromonas gingivalis, on human aortic
smooth muscle cell (hAOSMC) proliferation as mechanisms of atherosclerosis. Cultured hAOSMCs
exposed to the supernatant of plasma incubated with P. gingivalis showed a marked transformation
from a contractile to proliferative phenotype, resulting in enhancement of cell growth. DNA micro-
array analysis revealed a P. gingivalis-dependent upregulation of S100A9 in hAOSMCs. Small inter-
ference-RNA for S100A9 dramatically attenuated the effect of P. gingivalis on transformation and
proliferation of hAOSMCs. Our data suggested that upregulation of S100A9 mediated by P. gingivalis
is an important event in the development of aortic intimal hyperplasia.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Porphyromonas gingivalis (P. gingivalis) is a gram-negative
anaerobic bacterium considered to be a periodontal pathogen that
causes severe periodontitis. Several epidemiologic studies have
strongly indicated the involvement of P. gingivalis in the develop-
ment of systemic diseases, in particular atherosclerosis [1–3].
However, there has been no deﬁnitive evidence or systematic
explanation about the precise involvement of P. gingivalis in the
mechanisms of development of such systemic diseases. We havechemical Societies. Published by E
lis; SMC, smooth muscle cell;
all interfering RNA; SMemb,
a).reported that the frequency of detection of P. gingivalis in speci-
mens from aneurysmal or atherosclerotic blood vessels from pa-
tients was markedly lower than that of other oral bacteria, such
as Streptococcus mutans (S. mutans) which is thought to be involved
in the pathogenesis of endocarditis [2]. Therefore, it remains un-
clear whether invasion of blood vessels by P. gingivalis is actually
essential and sufﬁcient to cause cardiovascular diseases. There
are numerous questions about the involvement of oral bacteria
in the development of systemic diseases.
In the present study, we have tried to clarify the precise
involvement of these bacteria in the mechanisms of development
of occlusive vascular diseases, such as atherosclerosis. For this pur-
pose, we used an in vitro human aortic smooth muscle cell
(hAOSMC) culture system. We clearly show that upregulation of
the S100 calcium-binding protein A9 by P. gingivalis is an impor-
tant event in the induction of hAOSMC transformation from a con-
tractile to proliferative phenotype, with resultant enhancement of
the cell growth. This is the ﬁrst report to indicate the involvementlsevier B.V. All rights reserved.
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opment of vascular diseases.2. Materials and methods
2.1. Reagents and antibodies
Anti-S100A9 polyclonal antibody was purchased from Santa
Cruz (Santa Cruz, CA). Anti-S100A9 monoclonal antibody was pur-
chased from Monosan (Uden, The Netherlands). Anti-non-muscle
myosin heavy chain (embryonic isoform of myosin heavy chain
(SMemb)) antibody was purchased from Yamasa Co. Ltd., (Chyo-
shi, Japan).
2.2. Bacteria strains
P. gingivalis OMZ314 was grown anaerobically at 37 C in trypti-
case soy broth supplementedwith yeast extract (1 mg/ml),menadi-
one (1 lg/ml), and hemin (5 lg/ml), as described previously [4,5].
2.3. Reaction of plasma with P. gingivalis
Blood samples were donated by ﬁve healthy volunteers who
had not ingested any medication 14 days before the sampling,B
0 24
Evalua
Cel
Mic
Normal Human
Aortic Smooth
Muscle Cells
(hAOSMC)
N
PB
Plasma c
Plasm
Plasm
Plasma P. gingivalis
Supernatant (Filtration)
Normal Human Aortic
Smooth Muscle Cells
A
Ev
0
Normal Human
Aortic Smooth
Muscle Cells
(hAOSMC)
siRNA
treatmen
S
from pl
Cell
Mic
Fig. 1. Schematic illustrations of experimental protocols. (A) Schematic protocol of hum
and applied to the hAOSMC culture system. (B) Schematic protocol of siRNA study. siRNA
P. gingivalis.and the plasma was prepared. Plasma (200 ll) was mixed with
bacterial suspensions (100 ll, 107 cfu) prepared by the serial dilu-
tion method, and incubated at 37 C for 6 h. At the end of the incu-
bation, P. gingivalis was removed by centrifugation and ﬁltration,
and the supernatant was collected. The protein concentrations in
the supernatants were measured using a BCA protein assay kit
(PIERCE).
2.4. Human aortic smooth muscle cell (hAOSMC) culture and
proliferation assay
Human aortic smooth muscle cells (hAOSMCs) were obtained
from Clonetics and maintained in SmBM-Bullet kit. The hAOSMCs
(at passages 3–6) were seeded at a density of 5  103 cells per well
and incubated overnight. At the end of the incubation, the culture
mediumwas discarded and replaced with 100 ll of SmBM contain-
ing 50 lg/ml of the supernatants of plasma + P. gingivalis (Fig. 1A).
After the stimulation by exposure of hAOSMCs to the supernatants,
the number of cells was measured using the TetraColor ONE Cell
Proliferation Assay System (SEIKAGAKU, Tokyo).
2.5. DNA microarray
To investigate the potential target molecules that are involved
in P. gingivalis-induced proliferation of hAOSMC, an exhaustive48 72 hours
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130 H. Inaba et al. / FEBS Letters 583 (2009) 128–134analysis of gene alterations using a DNAmicroarray was performed
[6,7]. In brief, hAOSMCs were exposed to the supernatant of plasma
+ P. gingivalis or plasma alone, then samples were collected at 12 h
after the incubation. Total RNA was prepared from treated
hAOSMC, and amino-allyl ampliﬁed RNA was then prepared from
the total RNA using an Amino-allyl MessageAmp aRNA kit (Ambion
Inc., Austin, TX). Amino-allyl ampliﬁed RNAs from each groups was
labelled by Cy3 or Cy5 using FluoroLink Cy3 or Cy5 mono-func-
tional Dye 5-Packs (Amersham Bioscience, London, UK), then ap-
plied to mouse gene chip system (Sigma Genosis Japan, Sapporo,
Japan). Expression of genes was detected by the ﬂuorescent inten-
sity of Cy3 and Cy5.
2.6. Small interfering RNA (siRNA) transfection and treatment with the
supernatant of plasma + P. gingivalis
The interfering sequences of the sense strand of S100A9 (cal-
granulin B) used were 50-CCUUCUCAGAUGGAGCGCAGCAUAA-30,
50-CCAGGACAAUCAGCUGAGCUUUGAG-30 and 50-CCUGUCAUGAG-
AAGCUGCAUGAGAA-30. For the transfection, S100A9 siRNAs or
negative control medium (Scramble siRNA, Invitrogen) solution
was added to SmBM containing Lipofectamine RNAiMAX. The cul-
tured hAOSMCs were seeded at a density of 1  104 cells per well
in 24-well tissue culture plates and incubated overnight. After
incubation, the culture medium was discarded and replaced withA
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Fig. 2. Stimulation of human aortic smooth muscle cell (hAOSMC) proliferation by plasm
after treatment with the supernatant of plasma + P. gingivalis, plasma alone or P. gingivalis
control. Each column represents the mean ± S.E.M. from 7 to 12 independent experimen
hAOSMCs 24, 48 and 72 h after the treatment with the supernatant of plasma + P. gingi
control. Each point represents the mean ± S.E.M. from 7 to 12 independent experimen
treatment with the supernatant of plasma + P. gingivalis or plasma. Marked transformati300 ll of SmBM. The transfection mixture was then added to the
cells at a ﬁnal concentration of siRNA of 12.5–100 nM along with
50 lg/ml of bacterial supernatants (Fig. 1C). Twenty-four hours
after the start of transfection, the medium was changed to SmBM
containing 50 lg/ml of the bacterial supernatants. The cell prolifer-
ation assay was performed 72 h after the incubation.
2.7. Statistical analysis
All results are expressed as mean ± S.E.M. Statistical compari-
sons were made using the Student’s t-test or Scheffe’s method after
analysis of variances (ANOVA). The results were considered signif-
icantly different at P < 0.05.
3. Results
3.1. Interaction P. gingivalis with plasma causes the proliferation of
hAOSMC
To investigate the effect of P. gingivalis on smooth muscle cells
(SMCs), we used an in vitro cultured hAOSMC culture system
(Fig. 1A). Based on our in vivo previous observations (unpublished
data), we hypothesized that contact of uncovered SMCs with P. gin-
givalis in the plasma after the endothelial cell-falling off is impor-
tant for the induction of SMC proliferation-induced hyperplasia.B
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gingivalis or P. gingivalis itself to the hAOSMC culture system to
reappear the condition of uncovered SMCs in vivo. Treatment with
plasma alone or P. gingivalis alone did not result in stimulation of
hAOSMC proliferative activity in comparison with that in the no-
treatment group (Fig. 2A). In contrast, addition of the supernatant
of plasma incubated with P. gingivalis dramatically stimulated the
growth of hAOSMCs in comparison with that in the plasma control
(plasma alone). The stimulation of cell growth by the supernatant
of plasma incubated with P. gingivalis was both bacterial cell num-
ber-dependent and time-dependent manners (Fig. 2B). In addition,
the dramatic alteration of the cell growth rate was not observed
within 24 h after the incubation (Fig. 2B).
Interestingly, marked morphological changes were observed in
the hAOSMCs treated with the supernatant of plasma incubated
with P. gingivalis as compared to the morphology in the plasmaA
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thesemorphologically transformed SMCs treated with the superna-
tant of plasma incubated with P. gingivalis also expressed SMemb
[8], a phenotypic marker of proliferative type of SMCs, (Fig. 3B).
These results indicate that the transformation of the hAOSMCs from
the contractile to proliferative phenotype was induced by exposure
of the cells to plasma with P. gingivalis treatment.
3.2. Target molecules involved in the SMC proliferation induced by P.
gingivalis
To investigate the potential target molecules that are involved
in P. gingivalis-induced transformation and stimulation of the pro-
liferative activity of the SMCs, we performed an exhaustive analy-
sis of gene alterations using a DNA microarray according to the
method previously described [6,7]. Genes encoding calcium-bind-Plasma controlis
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132 H. Inaba et al. / FEBS Letters 583 (2009) 128–134ing proteins, especially S100A9 (4.95-fold), were accounted for the
majority of the gene alterations, although several chemokines such
as chemokine ligand 3 (2.66-fold) were also upregulated (data not
shown). To conﬁrm the results, we investigated the alterations of
gene expressions in the hAOSMCs treated with the supernatant
of plasma incubated with P. gingivalis. We performed real-time
PCR analysis to conﬁrm the upregulation of S100A9 in the
hAOSMCs exposed to the supernatant of plasma incubated with
P. gingivalis for 12 h (Fig. 3A). In addition, marked increase in the
expression of S100A9 on both the cell surface and in the cytosol
was observed in the hAOSMCs exposed to the supernatant of plas-
ma incubated with P. gingivalis as compared with that in the plas-
ma control group by the confocal microscopic observations
(Fig. 3C). Furthermore, the expression of S100A9 was closely corre-
lated with the expression of SMemb (Fig. 3B). It is well known that
the expression of SMemb is the proof of the transformation of
SMCs from the contractile to proliferative phenotype [8]. There-Negative control Sequence-1
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from the contractile to proliferative phenotype was induced by the
exposure of the cells to plasma with P. gingivalis treatment.
3.3. Knockdown of S100A9 attenuates increase in hAOSMC growth
induced by exposure to plasma plus P. gingivalis
To conﬁrm whether S100A9 is one of the targets in the induc-
tion of transformation and stimulation of the proliferative activity
of the SMCs, we designed small interference-RNAs (siRNAs) for
S100A9 and applied them to the hAOSMC culture system
(Fig. 1B). All of the three siRNA sequences (Sq-1, Sq-2 and Sq-3)
that we designed effectively and speciﬁcally suppressed the
expression of the S100A9 protein that was induced following expo-
sure of the cells to the supernatant of plasma incubated with P. gin-
givalis (Fig. 4A). Under our experimental condition, all of siRNA
sequences for S100A9 also inhibited the increased cell growth ofSequence-2 Sequence-3
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with P. gingivalis (Fig. 4C). In addition, transformation of hAOSMCs
from the contractile to a proliferative phenotype induced by the
supernatant of plasma incubated with P. gingivalis was also inhib-
ited by the siRNA sequences (Fig. 4B). The expression of SMemb by
the treatment with the supernatant of plasma incubated with P.
gingivalis was also attenuated by the siRNA treatment. These re-
sults suggest that upregulation of S100A9 in the SMCs induced
by the plasma + P. gingivalis treatment is involved in the mecha-
nisms underlying the transformation and proliferation of SMCs in-
volved in the hyperplasia in vivo. We also investigated activation of
MAPK pathway, one of the possible mechanisms to induce the cell
proliferation, on hAOSMC treated with plasma plus P. gingivalis.
The marked activation of MAPK pathway on hAOSMCs treated with
plasma plus P. gingivalis was observed (Fig. 4D). In addition, the
activation of MAPK by plasma plus P. gingivalis was attenuated
by the treatment with siRNA for S100A9 (Fig. 4D).4. Discussion
In the present study, we clearly suggest that upregulation of the
S100 calcium-binding protein A9 by P. gingivalis is the important
event in the induction of hAOSMC transformation from a contrac-
tile to proliferative phenotype, with resultant enhancement of the
cell growth. This is the ﬁrst report to indicate the involvement of P.
gingivalis and the possible mechanisms involved in the develop-
ment of vascular diseases.
The treatment of the hAOSMCs with plasma plus P. gingivalis-in-
duced transformation and dramatically increased the growth of the
hAOSMCs. These results indicated that proliferation of SMCs was
induced by the supernatant of plasma plus P. gingivalis in vitro
without other factors, such as activation of inﬂammatory cells or
elevated serum cholesterol level. Upregulation of S100A9 was also
conﬁrmed in the transformed hAOSMCs treated with the superna-
tant of plasma plus P. gingivalis, because the morphological
changes to a proliferative phenotype were accompanied with the
expression of S100A9 and SMemb. We, therefore, attempted to
determine whether S100A9 might be the actual target for the
transformation of the cells to a proliferative phenotype.
Knockdown of S100A9 protein by speciﬁc siRNA dramatically
diminished the increase in growth of the hAOSMCs induced by
the treatment with plasma plus P. gingivalis, indicating that
S100A9 is the potential target in the induction of hAOSMC prolifer-
ation. The knockdown of S100A9 by speciﬁc siRNA also attenuated
the morphological change of hAOSMC from contractile to prolifer-
ative phenotype accompanied with the expression of SMemb.
These results suggest that upregulation of the S100A9 by plasma
incubated with P. gingivalis is the important event in the induction
of hAOSMC transformation from a contractile to proliferative phe-
notype, with resultant enhancement of the cell growth.
Although it has been reported that S100A9 is a member of the
S100 calcium-binding protein family, its biological roles and mech-
anisms are still unclear [9]. Because of the expression in inﬂamma-
tion and cancer, it has been suggested that S100A9 may play an
important role in cell proliferation [9]. In our experimental condi-
tions, the expression of S100A9 was observed on SMCs. In addition,
siRNAs for S100A9 inhibited the increased proliferation of
hAOSMCs treated with the supernatant of plasma incubated with
P. gingivalis. In contrast, the treatment with siRNAs for S100A9 to
hAOSMCs in the absence of the supernatant of plasma incubated
with P. gingivalis did not show the signiﬁcant inhibition of cell pro-
liferation in comparison to that treated with negative control siR-
NA (data not shown). We, therefore, speculate that ectopic
expression of S100A9 in SMCs causes the phenotypic transforma-
tion from contractile to proliferative, although S100A9 originallyexpresses in macrophage or other inﬂammatory cells. In fact, we
observed the activation of MAPK pathway on hAOSMCs treated
with plasma plus P. gingivalis and attenuation of MAPK activation
by siRNA for S100A9. The ectopic expression of S100A9 may also
cause the migration of SMCs in to intimal area, resulting in the
SMC-dependent atherosclerosis.
How is S100A9 upregulated by treatment with the supernatant
of plasma plus P. gingivalis? The upregulation of S100A9 and con-
sequent stimulation of the cell growth were not observed follow-
ing treatment with P. gingivalis alone, in the absence of plasma.
These results indicate that the presence of as yet unidentiﬁed sub-
stances in the plasma-added suspension of P. gingivalis might be
responsible for the upregulation. Further investigations will be
required.
Our results presented here may indicate the possible mecha-
nisms to cause the SMC-dependent occlusive aortic diseases, such
as Burger’s disease and aneurysmal hyperplasia, induced by P. gin-
givalis. Burger’s disease, an occlusive vascular disease, occurs in
persons with P. gingivalis infection, despite of the absence of eleva-
tion of the plasma cholesterol level [10–12]. It is well known that
smoking, as well as P. gingivalis infection is the most important risk
factor for Burger’s disease [11]. Smoking induces free radical gen-
eration in blood, which causes injury to endothelial cells (ECs).
Consequent dysfunction or detachment of the ECs leads to direct
exposure of the vascular SMCs to P. gingivalis, which may induce
the phenotypic alteration of SMCs from contractile to proliferative
type. The transformation of SMCs might trigger the onset of Bur-
ger’s disease. Namely, simultaneous presence of P. gingivalis in
the bloodstream (interaction of P. gingivalis with plasma) and EC
injury are essential and sufﬁcient to cause vascular disease in vivo.
In conclusion, we showed that upregulation of the S100A9 by P.
gingivalis was the possible mechanism to cause the SMC transfor-
mation, resulting in the SMC proliferation. Our data presented here
may provide a new therapeutic target for the prevention of oral
bacteria-induced vascular diseases.
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